DQ — Deck
DAQO manufactures high-purity polysilicon for the solar photovoltaic industry from two facilities in western China, selling exclusively to Chinese wafer and module makers under framework contracts priced at prevailing spot rates.
Revenue fell 86% from peak as polysilicon prices crashed below cash cost.
Polysilicon ASP collapsed from $30+/kg in 2022 to under $5/kg as Chinese capacity tripled to over 2 million MT. DAQO ran at 40% utilization in FY2025, producing 123,652 MT of its 305,000 MT capacity. The stock trades at cash-per-share, pricing the entire manufacturing base at zero.
A $1.9B cash fortress — but can the company access it?
- Bull case. $1.9B cash with zero debt gives DAQO over a decade of survival runway at FY2025 burn rates. As a low-cost producer with newer facilities, it outlasts competitors in a war of attrition. At 0.45x book, the equity is a deeply discounted call option on the polysilicon cycle.
- Bear case. The cash sits in Chinese subsidiaries behind capital controls, statutory reserve requirements, and 10% withholding tax. The Cayman holdco has never paid a dividend. Cash has declined $1.6B in three years with no recovery in sight — Q1 FY2026 revenue collapsed to $27M.
- The deciding variable. Polysilicon spot price. At $5/kg, everyone loses. At $10/kg, DAQO breaks even and the asset base has value. The cycle turns when 500,000+ MT of capacity exits — no confirmed shutdowns yet despite government rhetoric.
A boom-bust commodity producer caught in the deepest polysilicon oversupply in history.
The boom (2020-2022). Solar installations surged globally, polysilicon prices spiked from $8/kg to $30+/kg, and DAQO earned $1.8B in a single year. The company 9x'd its capacity from 35,000 MT to 305,000 MT.
The bust (2023-present). Chinese polysilicon capacity tripled from 600,000 MT to over 2 million MT. Prices crashed below cash cost. DAQO's gross margins swung from +74% to -21% — a 95-percentage-point collapse. Industry utilization is around 50%.
Today. DAQO has stopped expanding, cut capex below depreciation, and is waiting for supply to rationalize. China's government has declared "anti-involution" a policy priority and proposed mandatory energy consumption standards that could force high-cost producers offline. The question is whether policy translates to actual capacity exits before the cash runs out.
Family-controlled with operational depth but governance gaps.
- CEO Xiang Xu owns 9.35% ($131M) and has been a director since founding. Took over from his father in August 2023. His daughter Xiaoyu Xu was promoted to Deputy CEO after one year at the company — credentialed (Wharton MBA, ex-J.P. Morgan) but unproven operationally.
- CFO Ming Yang is a standout — ex-McKinsey, ex-Coatue Management hedge fund, Cornell MBA. His capital markets expertise is critical for a Chinese company navigating US public markets during a downturn.
- Governance grade: B-. No individual compensation disclosure (FPI exemption), combined chairman/CEO role, no dividends despite years of massive profitability, and PFIC classification creating structural tax friction for US holders.
Watchlist — balance sheet protects, but the cycle has not confirmed a bottom.
- For. $1.9B cash, zero debt, 5.4x current ratio. Cash per share ($29) roughly equals stock price — fundamental downside is floored unless impairment materializes.
- For. China's anti-involution policy with mandatory energy standards creates a regulatory path to supply rationalization. DAQO's newer facilities meet the threshold; smaller competitors do not.
- Against. Q1 FY2026 revenue collapsed to $27M with -$139M gross loss. The Q3-Q4 FY2025 recovery was a seasonal blip. No confirmed capacity exits despite government rhetoric.
- Against. Cash is trapped in China, the manufacturing base faces impairment risk at 40% utilization, and PFIC status structurally limits the US investor base.
Watchlist to re-rate: 1) Polysilicon spot prices — sustained above $8/kg signals a turn. 2) Confirmed capacity exits from named Chinese producers totaling 200k+ MT. 3) Q2 FY2026 revenue above $150M would validate recovery trend.